Anil S Modak

US Patent:

6890305, May 10, 2005

Filed:

Feb 26, 2003

Appl. No.:

10/372982

Inventors:

Yasuo Irie - Reading MA, US
Anil S. Modak - Methuen MA, US

Assignee:

Cambridge Isotope Laboratories - Andover MA

International Classification:

A61B005/00

US Classification:

600532, 73 233, 422 84

Abstract:

The present invention relates to an assay for evaluating alveolar exchange of oxygen. A C-labeled substrate, such as C-sodium bicarbonate is administered to a subject by oral or iv intake, and exhaled COis measured. The COin expired breath can be collected at various time points following administration of the substrate and measured in Δ per mil with a mass analyzer or photometer, such as an IR spectrometer. This process can be used as a diagnostic test for the indication of, treatment and/or evaluation of the severity of respiratory tract diseases or infections.

US Patent:

7833744, Nov 16, 2010

Filed:

Aug 31, 2007

Appl. No.:

11/848750

Inventors:

David A. Flockhart - Indianapolis IN, US
Zeruesenay Desta - Carmel IN, US
Anil S. Modak - Haverhill MA, US
Yasuhisa Kurogi - North Andover MA, US

Assignee:

Cambridge Isotope Laboratories, Inc. - Andover MA

International Classification:

C12Q 1/26

US Classification:

435 25, 424 91

Abstract:

The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by the subject upon intravenous or oral administration of a C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite COin expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.

US Patent:

20060188444, Aug 24, 2006

Filed:

Feb 23, 2005

Appl. No.:

11/062554

Inventors:

Yasuo Irie - Woburn MA, US
Anil Modak - Methuen MA, US
Tadashi Mukai - Naruto-shi, JP

International Classification:

A61K 49/00

US Classification:

424009100

Abstract:

The present invention provides a highly accurate method for monitoring patient or subject compliance with a medication prescription by collecting a sample of the exhaled air. The method of the present invention is easy and little burdens the patient or subject. The method comprises the steps of: (i) prescribing a patient or subject ingestion of at least one biologically active agent and at least one carbon isotope-labeled lipid, (ii) obtaining a sample of the patient's or subject's exhaled air, (iii) measuring the ratio of the carbon isotope-labeled COrelative to COin the sample; and (iv) confirming the ingestion of the prescribed biologically active agent based on the ratio of the carbon isotope-labeled COrelative to CO.

US Patent:

20070003481, Jan 4, 2007

Filed:

Jun 30, 2006

Appl. No.:

11/479396

Inventors:

Anil Modak - Haverhill MA, US
Yasuhisa Kurogi - North Andover MA, US

International Classification:

A61K 49/00

US Classification:

424009100

Abstract:

The present invention relates, generally to a method of determining and assessing L-3,4-dihydroxyphenylalanine (a.k.a., Levodopa; L-dopa; or LD) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by the subject upon intravenous or oral administration of a C-labeled substrate, such as levodopa. The present invention is useful as an in vivo phenotype assay for individualizing LD/Carbidopa(CD) therapy in Parkinsons disease patients by optimizing the dose and timing of the dose of dopamine decarboxylase (DDC) inhibitor like CD for systemic suppression of dopamine metabolism by evaluating DDC enzyme activity using the metabolite COin expired breath.

US Patent:

20070026480, Feb 1, 2007

Filed:

Apr 14, 2006

Appl. No.:

11/404965

Inventors:

Anil Modak - Methuen MA, US
Yasuo Irie - Reading MA, US
Yasuhisa Kurogi - North Andover MA, US

International Classification:

C12Q 1/26

US Classification:

435025000

Abstract:

The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by a the subject upon intravenous or oral administration of a C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite COin expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.

US Patent:

20090041662, Feb 12, 2009

Filed:

Feb 22, 2006

Appl. No.:

11/884876

Inventors:

Irie Yasuo - Tokushima, JP
Anil Modak - Haverhill MA, US
Tadashi Mukai - Tokushima, JP

International Classification:

A61K 51/04
C07C 57/02
G01N 33/497

US Classification:

424 181, 554223, 73 233

Abstract:

The present invention provides a highly accurate method for monitoring patient or subject compliance with a medication prescription by collecting a sample of the exhaled air. The method of the present invention is easy and little burdens the patient or subject.The method comprises the steps of:

US Patent:

20100329979, Dec 30, 2010

Filed:

Sep 2, 2010

Appl. No.:

12/874350

Inventors:

Anil S. Modak - Haverhill MA, US
Yasuo Irie - Tokushima-shi, JP
Yasuhisa Kurogi - North Andover MA, US

International Classification:

A61K 51/08

US Classification:

424 181

Abstract:

The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by a the subject upon intravenous or oral administration of a C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite COin expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.

US Patent:

20110111510, May 12, 2011

Filed:

Nov 9, 2010

Appl. No.:

12/942280

Inventors:

David A. Flockhart - Indianapolis IN, US
Zeruesenay Desta - Carmel IN, US
Anil S. Modak - Haverhill MA, US
Yasuhisa Kurogi - North Andover MA, US

International Classification:

G01N 37/00
C07D 401/12

US Classification:

436 56, 5462737

Abstract:

The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2C19) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of COexhaled by the subject upon intravenous or oral administration of a C-labeled CYP2C19 substrate compound. The present invention is useful as anon-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite COin expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.